Celldex Therapeutics PT Raised to $45.00 at Leerink Swann (CLDX)
Research analysts at Leerink Swann boosted their target price on shares of Celldex Therapeutics (NASDAQ:CLDX) to $45.00 in a report released on Monday, StockRatingsNetwork.com reports. Leerink Swann’s price target indicates a potential upside of 55.39% from the stock’s previous close.
Celldex Therapeutics (NASDAQ:CLDX) opened at 28.96 on Monday. Celldex Therapeutics has a 52 week low of $5.02 and a 52 week high of $29.31. The stock has a 50-day moving average of $22.66 and a 200-day moving average of $16.44. The company’s market cap is $2.345 billion.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 51.7% on a year-over-year basis. Analysts expect that Celldex Therapeutics will post $-0.97 EPS for the current fiscal year.
A number of other firms have also recently commented on CLDX. Analysts at Wedbush reiterated a “buy” rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note to investors on Tuesday, September 17th. They now have a $35.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $25.00 to $29.00 in a research note to investors on Tuesday, September 17th. They now have a “buy” rating on the stock. Finally, analysts at Thomson Reuters/Verus upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a “sell” rating to a “hold” rating in a research note to investors on Monday, September 16th.
One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $29.38.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.